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Abstract: Chemotherapy is one of the main treatments used to combat cancer. A great 
number of antitumor compounds are natural products or their derivatives, mainly produced 
by microorganisms. In particular, actinomycetes are the producers of a large number of 
natural products with different biological activities, including antitumor properties. These 
antitumor compounds belong to several structural classes such as anthracyclines, 
enediynes, indolocarbazoles, isoprenoides, macrolides, non-ribosomal peptides and others, 
and they exert antitumor activity by inducing apoptosis through DNA cleavage mediated 
by topoisomerase I or II inhibition, mitochondria permeabilization, inhibition of key 
enzymes involved in signal transduction like proteases, or cellular metabolism and in some 
cases by inhibiting tumor-induced angiogenesis. Marine organisms have attracted special 
attention in the last years for their ability to produce interesting pharmacological lead 
compounds.  
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1. Introduction  
 
Actinomycetes, characterized by a complex life cycle, are filamentous Gram-positive bacteria 
belonging to the phylum Actinobateria that represents one of the largest taxonomic units among the 18 
major lineages currently recognized within the domain Bacteria [1]. Actinobacteria are widely 
distributed in terrestrial and aquatic ecosystems, especially in soil, where they play a crucial role in the 
recycling of refractory biomaterials by decomposing complex mixtures of polymers in dead plant, 
animal and fungal materials. They are important in soil biodegradation and humus formation by the 
recycling of nutrients associated with recalcitrant polymers such as keratin, lignocelluloses and chitin 
[2-4] and produce several volatile substances like geosmin responsible of the characteristic “wet earth 
odor” [5]. They also exhibit diverse physiological and metabolic properties, such as the production of 
extracellular enzymes [3,6]. 
Around 23,000 bioactive secondary metabolites produced by microorganisms have been reported 
and over 10,000 of these compounds are produced by actinomycetes, representing 45% of all bioactive 
microbial metabolites discovered [7]. Among actinomycetes, around 7,600 compounds are produced 
by Streptomyces species [7]. Many of these secondary metabolites are potent antibiotics, which has 
made streptomycetes the primary antibiotic-producing organisms exploited by the pharmaceutical 
industry [7]. Members of this group are producers, in addition, of clinically useful antitumor drugs 
such as anthracyclines (aclarubicin, daunomycin and doxorubicin), peptides (bleomycin and 
actinomycin D), aureolic acids (mithramycin), enediynes (neocarzinostatin), antimetabolites 
(pentostatin), carzinophilin, mitomycins and others [8,9]. However, the search for novel drugs is still a 
priority goal for cancer therapy, due to the rapid development of resistance to multiple 
chemotherapeutic drugs. In addition, the high toxicity usually associated with cancer chemotherapy 
drugs and their undesirable side effects increase the demand for novel antitumor drugs active against 
untreatable tumors, with fewer side effects and/or with greater therapeutic efficiency [10].  
Progress has been made recently on drug discovery from actinomycetes by using high-throughput 
screening and fermentation, mining genomes for cryptic pathways, and combinatorial biosynthesis to 
generate new secondary metabolites related to existing pharmacophores [11]. In addition, in the last 
years the isolation of marine actinomycetes has been a great source of new compounds and their 
isolation all around the globe, from shallow costal sediments to the deepest sediments from the 
Mariana Trench, demonstrates that actinomycetes are ubiquitous in marine sediments, but at lower 
numbers than in soil [12-24]. The oceans are highly complex environments and house a diverse 
assemblage of microbes that occur in environments with extreme variations in pressure, salinity, and 
temperature. The oceans cover around 70% of the Earth's surface and present themselves as an 
unexplored area of opportunity. Marine microorganisms encompass a complex and diverse assemblage 
of microscopic life forms, of which it is estimated that only 1% has been cultured or identified [25]. In 
addition, marine actinomycetes have been found in symbiosis with different marine invertebrates, 
especially sponges [26,27]. Marine actinomycetes have attracted great attention since they have 
developed unique metabolic and physiological capabilities that not only ensure survival in extreme 
habitats, but also offer the potential to produce compounds with antitumor and other interesting 
pharmacological activities that would not be observed in terrestrial microorganisms [28-32], perhaps 
because of their close relationships with marine eukaryotic organisms including mammals [11,26]. Mar. Drugs 2009, 7                                    
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However, one of the main problems associated with marine actinomycetes is the difficulty often found 
for their culture, due to specific requirements like sea salt, since in some cases these microorganisms 
are obligate halophiles [33]. There are a number of reports on techniques and approaches for accessing 
previously uncultured soil actinomycetes and the biosynthesis gene clusters they harbor [34,35]. In the 
case of marine actinomycetes these studies are only beginning, but there have already been several 
attempts to optimize their isolation and growth from several sources [26,36,37] as well as the 
improvement of the fermentation process for the production of specific compounds [33,38,39] and the 
development of tools to facilitate the genetic manipulation of the isolated biosynthesis gene   
clusters [40,41]. 
In this review we focus on novel antitumor compounds identified from marine actinomycetes and 
classified them in terms of their chemical structure (Table 1), covering the literature until   
February 2009. 
 
Table 1. Antitumor compounds produced by marine actinomycetes.  
Compound Structural  type  Organism  Ref. 
1-hydroxy-1-norresistomycin Polyketide  Streptomyces chinaensis AUBN1/7 
Streptomyces sp. B8005 
87 
88 
1,6-phenazinediol   Phenazine  Actinomadura sp. M048  116 
1,8-dihydroxy-2-ethyl-3-
methylanthraquinone  
Polyketide  Streptomyces sp. FX-58  86 
3,6-disubstituted indoles   Indole  Streptomyces sp. BL-49-58-005  167 
4a,8a-dimethyl-6-(2-methyl-
propenyloxy)-
3,4,4a,4b,5,6,8a,9-octahydro-
1H-phenanthren-2-one 
Isoprenoid  Actinobacterium sp. MS1/7  143 
Actinofuranones   Polyketide  Streptomyces sp. CNQ766  65 
Altemicidin   Isoprenoid  Streptomyces sioyaensis SA-1758  135, 136 
Ammosamides   Pyrroloiminoquinone  Streptomyces sp. CNR-698  162 
Arcyriaflavin A  Indolocarbazole  Actinomycete sp. Z2039-2  153 
Arenamides Non-ribosomal  peptide  Salinispora arenicola CNT-088  117 
Arenicolides   Polyketide  Salinispora arenicola CNR-005  44 
Aureoverticillactam  Polyketide  Streptomyces aureoverticillatus NPS001583 53 
Bohemamines   Pyrrolizidine  Streptomyces sp. CNQ-583  163 
Butenolides Butenolide  Streptoverticillium luteoverticillatum 11014  173 
Caboxamycin   Benzoxazole  Streptomyces sp. NTK 937  172 
Chalcomycin   Polyketide   Streptomyces sp. M491  49 
Chalcomycin B  Polyketide  Streptomyces sp. B7064 
Streptomyces sp. M491 
50 
49 
Chandrananimycins Phenoxazin-3-one  Actinomadura sp. M048  179 
Chartreusin Polyketide  Streptomyces sp. QD518  75 
Chinikomycins Polyketide Streptomyces sp. M045  57 
Chlorinated dihydroquinones   Isoprenoid  Actinomycete isolate CNQ-525  141 
Cyanosporasides Polyketide  Salinispora pacifica CNS103  66 
Daryamides Polyketide  Streptomyces sp. CNQ-085  58 
Echinosporins   Acetal-lactone  Streptomyces albogriseolus A2002  180 
Fridamycin D  Polyketide  Streptomyces sp. B6921  80 
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Table 1. Cont. 
Griseorhodin A  Polyketide  Streptomyces sp. JP95  100, 103 
Gutingimycin Polyketide  Streptomyces sp. B8652  84 
Himalomycins Polyketide Streptomyces sp. B6921  80 
IB-0028   Polyketide  Actinomadura sp. BL-42-PO13-046  98, 99 
IB-96212   Polyketide  Micromonospora sp. L-25-ES25-008  47, 48 
Iodinin Phenazine  Actinomadura sp. M048  179 
K252c  Indolocarbazole  Actinomycete strain Z2039-2  153 
Komodoquinones   Polyketide  Streptomyces sp. KS3  73, 74 
Lajollamycin Polyketide/non-ribosomal 
peptide 
Streptomyces nodosus NPS007994  132 
Lucentamycins Non-ribosomal  peptide  Nocardiopsis lucentensis CNR-712  110 
Lynamycins Indolocarbazole  Marinispora sp. NPS12745  155 
Manumycin A  Polyketide  Streptomyces sp. M045  57 
Marinomycins Polyketide Marinispora sp. CNQ-140  54 
Marinones  Isoprenoid  Actinomycete isolate CNH-099  137-139 
Marineosins Polypyrrole  Streptomyces sp. CNQ-617  156 
Marmycins Polyketide  Streptomyces sp. CNH990  94 
Mechercharmycins Non-ribosomal  peptide  Thermoactinomyces sp. YM3-251  111 
Metacycloprodigiosin Prodigiosin  Saccharopolyspora sp. nov.  157 
Nonactin   Polyketide  Streptomyces sp. KORDI-3238  70 
Pacificanones   Polyketide   Salinispora pacifica CNS-237  63 
Parimycin Polyketide  Streptomyces sp. B8652  82 
Piericidins Polyketide  Streptomyces sp. YM14-060  67, 69 
Piperazimycins Non-ribosomal  peptide  Streptomyces sp. CNQ-593  120 
Proximicins   Non-ribosomal peptide  Verrucosispora sp. MG-37  
Verrucosispora maris AB-18-032 
107, 109 
108, 109 
Questiomycins   Phenoxazin-3-one  Actinomadura sp. M048  179 
Rabelomycin Polyketide  Streptomyces sp. B6921  80 
Resitoflavine Polyketide  Streptomyces chinaensis AUBN1/7 
Streptomyces sp. B8005 
87, 93 
88 
Resistomycin   Polyketide  Streptomyces sp. B8005 
Streptomyces sp. B4842 
88 
88 
Saliniketals Polyketide  Salinispora arenicola CNR-005  45 
Salinipyrones   Polyketide   Salinispora pacifica CNS-237  63 
Salinosporamides Polyketide/non-ribosomal 
peptide 
Salinispora tropica CNB-392 
Salinispora tropica CNB-440 
Salinispora tropica CNB-476 
Salinispora tropica NPS000456 
64, 121, 
126 
122, 131 
125, 131 
128 
Sporolides Polyketide  Salinispora tropica CNB-392  64 
SS-228 Y  Polyketide   Chainia sp. SS-228  95, 97 
Staurosporins Indolocarbazole  Streptomyces sp. KS3 
Micromonospora sp. L-31-CLCO-002  
Streptomyces sp. QD518 
74 
151 
75 
Streptochlorin   Indole  Streptomyces sp. 04DH110  168-171 
Streptokordin   Methylpyridine  Streptomyces sp. KORDI-3238.  70 
Streptopyrrolidine   Tetrahydropyrrole  Streptomyces sp. KORDI-3973  161 
Tetracenomycin D  Polyketide  Streptomyces sp. B8005  88 
Thiocoraline Non-ribosomal  peptide  Micromonospora sp. L-13-ACM2-092   112, 113 Mar. Drugs 2009, 7                                    
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Table 1. Cont. 
T-Muurolol Isoprenoid  Streptomyces sp. M491  49, 140 
Trioxacarcins Polyketide  Streptomyces sp. isolate B8652  83 
Undecylprodigiosin Prodigiosin  Saccharopolyspora sp. nov.  157 
ZHD-0501   Indolocarbazole  Actinomadura sp. 007  152 
 
2. Polyketides  
 
Polyketides are a large family of natural products produced by step-wise decarboxylative Claisen-
type condensation of acyl-CoA precursors, reactions catalyzed by polyketide synthases (PKSs). The 
carbon skeleton of polyketides may be further reduced and modified based on the programming 
encoded by different domains present in PKSs with ketoreductase, dehydratase and enoylreductase 
activities. Three types of PKSs are known to date: type I PKSs are multifunctional enzymes organized 
into modules, type II PKSs are multienzyme complexes carrying out a single set of activities and type 
III PKSs, also known as chalcone synthase-like PKSs, are iteratively acting condensing   
enzymes [42,43]. 
A high number of type I polyketide derived compounds with antitumor activity have been isolated 
from marine actinomycetes. Such is the case of arenicolides (Figure 1), 26-membered polyunsaturated 
macrolactones, produced by the obligate marine actinomycete Salinispora arenicola strain CNR-005 
isolated from a marine sediment sample collected at a depth of 20 m from the coastal water around the 
island of Guam.  
In particular, arenicolide A was found to exhibit moderate cytotoxicity toward the human colon 
adenocarcinoma cell line HCT-116 with an IC50 of 30 μg/mL [44]. Two bicyclic polyketides, 
saliniketal A and B (Figure 1), were also isolated from the same strain of S. arenicola. Using cultures 
of human bladder carcinoma T24 cells in conjunction with terephthalic acid, a potent tumor promoter 
that induces ornithine decarboxylase (ODC), saliniketals were found to inhibit ODC induction with 
IC50  values of 1.95 and 7.83 µg/mL, respectively [45]. ODC, an important target for the 
chemoprevention of cancer, is a directed transcriptional target of the oncogene myc and is 
overexpressed in various tumor cells [46]. 
Several macrolactones have been reported in addition to the arenicolides (Figure 1). IB-96212, a 
26-membered macrolide that contains a spiroketal lactone structure, is produced by Micromonospora 
sp. L-25-ES25-008 isolated from a sponge collected at the Indian Ocean near the coast of Mozambique 
[47]. This compound showed cytotoxic activity against mouse leukemia P-388 and human lung non-
small cell A-549, colon adenocarcinoma HT-29 and melanoma MEL-28 cell lines. The activity against 
P-388 cell line was four orders of magnitude higher than the activity against A-549, HT-29 and MEL-
28 cell lines [48]. Chalcomycin, a 16-membered macrolide, is produced by Streptomyces sp. M491 
isolated from the Qingdao coast (China) [49]. In addition, chalcomycin and the related compound 
chalcomycin B have been isolated from Streptomyces strain B7064 found in mangrove sediments in 
Hawaii [50]. Chalcomycin has been found to inhibit protein synthesis in HeLa human cervix 
carcinoma cell line [51]. The biosynthesis gene cluster of this compound was isolated and 
characterized from S. bikiniensis [52]. Aureoverticillactam is a 22-membered macrocyclic lactam 
produced by S. aureo-verticillatus NPS001583 isolated from marine sediments. Aureoverticillactam Mar. Drugs 2009, 7                                    
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was found to possess moderate growth inhibitory activity against human colorectal adenocarcnioma 
HT-29, Jurkat leukemia and mouse melanoma B16F10 cell lines [53]. 
 
Figure 1. Polyketide compounds arenicolides and saliniketals produced by S. arenicola 
CNR-005 and other macrolides and macrolactams. 
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To a novel class of polyketides belong marinomycins (Figure 2), unusual macrodiolides composed 
of dimeric 2-hydroxy-6-alkenyl-benzoic acid lactones with conjugated tetraene-pentahydroxy 
polyketide chains, produced by Marinispora sp. CNQ-140 isolated from a sediment sample collected 
at a depth of 56 m offshore of La Jolla, California. These compounds inhibit cancer cell proliferation 
with an average LC50 of 0.2-2.7 µM against the NCI’s 60 cancer cell line panel. Marinomycin A 
showed significant tissue type selectivity being more active against human melanoma cell lines LOX 
IMVI, M14, SK-MEL-2, SK-MEL-5, UACC-257, and UACC-62. The most sensitive strain was 
melanoma SK-MEL-5 with an LC50 of 5.0 nM. Marinomycins B and C also showed potent activities 
with average LC50 values of 0.9 and 0.2 µM, respectively. The potent and selective antitumor activity 
of these compounds suggests a specific, but as yet unknown, mechanism of action [54]. 
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The manumycins (Figure 3) constitute a class of compounds with antibiotic, cytotoxic, and other 
biological activities. It has been reported that manumycin A and its analogues inhibit Ras farnesyl 
transferase and the growth of Ki-ras-activated murine fibrosarcoma in mice [55,56]. The side chains in 
manumycins appear to be a typical polyketide-derived moiety, differing with respect to their 
combinations of starter and elongation units. The central cyclohexene ring may be derived from the 
polyketide as in the case of manumycins or from some modified amino acid like 3-amino-5-
hydroxybenzoic acid. Manumycin A and chinikomycins A and B (the quinone form of chinikomycin 
A) were isolated from Streptomyces sp. M045 derived from sediment of Jiaozhou Bay in China. 
Chinikomycins A and B showed moderate antitumor activity. Chinicomycin A selectively inhibited 
proliferation in cell lines of mammary cancer MAXF 401NL (IC50 of 2.41 µg/mL), melanoma MEXF 
462NL (IC50 of 4.15 µg/mL), and renal cancer RXF 944L (IC50 of 4.02 µg/mL). Chinikomycin B 
showed selective antitumor activity against the mammary cancer cell line MAXF 401NL (IC50 of  
3.04 µg/mL) [57]. Daryamides belong also to the manumycin family of compounds. They were 
isolated from Streptomyces strain CNQ-085 obtained from marine sediment collected at a depth of 50 
m off San Diego coast, California. Daryamides A to C and (2E,4E)-7-methylocta-2,4-dienoic acid 
amide were subjected to cytotoxicity evaluation against the human colon carcinoma cell line HCT-116 
showing that daryamide A exhibited significantly more potent cancer cell cytotoxicity, with an IC50 of 
3.15 µg/mL, than daryamides B and C [58]. 
 
Figure 2. Structures of marinomycins. 
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Even though it is not produced by a marine actinomycete we include in this review the antitumor 
compound lissoclinolide (Figure 3) isolated from the marine ascidian Lissoclinum patella [59]. This 
compound was originally isolated from a fungus and a soil actinomycete [60,61], which points to an 
actinomycete associated to L. patella as the true source of lissoclinolide. This compound, a small non-
nitrogenous lactone with a putative polyketide origin probably synthesized by a type I PKS, was able 
to inhibit cell growth in various mammalian tumor lines at an average IC50 of 395 nM, and in 
particular the human colon tumor COLO 205, HCC-2998, HCT-116 and HCT-15 cell lines which 
resulted in a strong arrest in the G2/M phase of the cell cycle [62]. 
 
Figure 3. Structures of manumycin type compounds and lissoclinolide. 
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Four new polyketides (Figure 4), salinipyrones (A and B), and pacificanones (A and B) have been 
isolated from cultures of the obligate marine actinomycete Salinispora pacifica CNS-237 found in a 
sediment sample collected in the Palau island, western Pacific Ocean. The biological activity of these 
compounds is currently being examined in diverse bioassays. In initial screening, the salinipyrones and 
the pacificanones displayed no significant activity in a cancer cytotoxicity assay using HCT-116 
human colon cancer cells. In an isolated mouse splenocyte model of allergic inflammation, 
salinipyrone A displayed moderate inhibition of interleukin-5 production by 50% at 10 μg/mL without 
measurable human cell cytotoxicity [63]. The same apparent lack of biological activity has been found 
also for the polyketides sporolide A and B (Figure 4) produced by Salinispora tropica strain CNB-392 
isolated from marine sediments near Chub Cay (Bahamas) [64] and actinofuranones A and B (Figure 
4) isolated from culture extract of Streptomyces strain CNQ766 derived from a sediment sample Mar. Drugs 2009, 7                                    
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collected from Guam [65]. Sporolides displayed no activity against human colon carcinoma HCT-116 
cells and showed no significant antibiotic activity [64]. Actinofuranones showed weak in vitro 
cytotoxicity against mouse splenocyte T-cells and macrophages with IC50 values of 20 µg/mL and 
were inactive against human colon carcinoma HCT-116 cells [65]. Cyanosporasides A and B (Figure 
4) are cyclopenta[a]indene glycosides structurally related to sporolides and proposed to be cyclization 
products of an enediyne precursor probably synthesized by an iterative type I PKS [42]. They have 
been isolated from the culture broth of S. pacifica strain CNS103 isolated from sediments collected at 
a depth of 500 m in Palau island. To date, limited testing has shown that cyanosporaside A has weak 
cytotoxicity against human colon carcinoma HCT-116 (IC50 30 µg/mL) [66].  
 
Figure 4. Structures of salinipyrones, pacificanones, sporolides, actinofuranones, 
cyanosporasides and piericidins type I polyketides and nonactin type II polyketide.  
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Piericidins C7 and C8 (Figure 4), probably synthesized by type I PKS, are produced by Streptomyces 
sp. YM14-060 isolated from an unidentified ascidian collected at Iwayama Bay, Palau Island [67]. The 
biological activity of piericidins was examined using rat glial cells transformed with the adenovirus 
E1A gene (RG-E1A-7), Neuro-2a mouse neuroblastoma cells, C6 rat glioma cells and 3Y1 rat normal 
fibroblast. The adenovirus E1A gene product inactivates the retinoblastoma tumor suppressor protein 
that plays an important role in cell-cycle and apoptosis control in mammalian cells and is inactivated 
during the development of a wide variety of cancers [68]. Piericidins C7 and C8 showed selective 
cytotoxicity against RG-E1A-7 cells (IC50 of 1.5 nM and 0.45 nM, respectively) and inhibited the 
growth of Neuro-2a cells (IC50 of 0.83 nM and 0.21 nM, respectively) without cytotoxic cell death. On 
the other hand, C6 rat glioma cells and 3Y1 rat normal fibroblast were not affected by piericidins [69]. 
Nonactin (Figure 4), a cyclic polyether also known as macrotetrolide, has been isolated from 
cultures of Streptomyces sp. KORDI-3238 isolated from a deep-sea sediment sample collected at Ayu 
Trough in the western Pacific Ocean [70]. The biosynthesis gene cluster of nonactin has previously 
been isolated and characterized from S. griseus DSM40695 [71] revealing that it is synthesized by a 
non-iteratively acting type II PKS that involves five ketosynthases and lacks the acyl carrier protein. 
Nonactin has been shown to be an effective inhibitor against the multidrug-resistant human 
erythroleukemia cell line K-562 [72]. 
 
Figure 5. Structures of several anthracyclines and anthracycline-like compounds. 
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Aromatic polyketides are synthesized by type II PKS and are further divided into different 
structural classes such as anthracyclines, angucyclines and tetracyclines among others. To the 
anthracycline family of compounds belongs komodoquinone A, and its aglycone, komodoquinone B 
(Figure 5) produced by Streptomyces sp. KS3 isolated from marine sediments. Komodoquinone A is a 
unique anthracycline, in which a previously unknown amino sugar is attached to C4 instead to C7 as in 
the most known anthracyclines [73]. Komodoquinone A was found to induce neuronal cell 
differentiation in the neuroblastoma cell line Neuro-2a at a concentration of 1 µg/mL, an activity not 
shown by doxorubicin. Treatment with komodoquinone A arrested Neuro-2a cells at the G1 phase 
while these treated with adriamycin were arrested at the G2/M phase. These data suggested that the 
amino sugar moiety attached to C4 might be important for neuritogenic activity of komodoquinone A, 
activity probably exerted by a mechanism different from the intercalation in DNA [73,74]. Another 
anthracycline related compound, chartreusin, has been isolated from cultures of Streptomyces sp. 
QD518 isolated from the Jiaozhou Bay of Quindao, China [75]. Chartreusin (Figure 5) is an aromatic 
glycosylated polyketide, currently in phase II clinical trials [76], that possesses an unusual bislactone 
synthesized through anthracycline intermediates that might undergo a series of oxidative 
rearrangements to generate the final bislactone structure. This particular biosynthetic process has been 
unraveled by the isolation of the chartreusin biosynthesis gene cluster from S. chartreusis [77]. 
Chartreusin has been shown to exert antitumor activity through binding to DNA, radical-mediated 
single-strand breaks and inhibition of topoisomerase II [78]. It possesses a significant 
chemotherapeutic activity against various tumor cell lines such as murine P388 and L1210 leukemia, 
and B16 melanoma cells [79]. Streptomyces sp. B6921 is the producer of several anthracycline C-
glycosides such as fridamycin D, himalomycin A and B, and the angucycline rabelomycin (Figure 5). 
Only antibiotic activity has been reported for these compounds [80]. However, other compounds 
analogous to fridamycin D and himalomycin A and B such as vineomycins have been shown to exhibit 
antitumor activity against Sarcoma-180 solid tumor in mice [81]. 
Several compounds of the anthraquinone family (Figure 6), closely related to anthracyclines, are 
produced by Streptomyces sp. isolate B8652 derived from a sediment of the Laguna de Términos at the 
Gulf of México. All these compounds, parimycin, trioxacarcins and gutingimycin, showed antitumor 
activities at different degrees [82-84]. It has been shown that trioxacarcin A forms a stable complex 
with dsDNA and the cleavage of these complexes provided the natural product gutingimycin by 
guanine abstraction [85]. Parimycin showed activity against human tumor cell lines of stomach cancer 
GXF 251L, lung cancer H460, LXFA 629L, and LXFL 529L, breast cancer MCF-7 and MAXF 
401NL, melanomas MEXF 462NL and MEXF 514L with IC70 values ranging from 0.9 to 6.7 μg/mL 
[82]. Trioxacarcins A to D showed pronounced antitumor activities with mean IC70 values ranging 
from 0.001 to 2.161 μg/mL against human tumor cell lines of colon cancer HT-29, melanoma MEXF 
514L, lung adenocarcinoma LXFA 526L, large cell lung cancer LXFL 529L and H-460, central 
nervous system SF-268, mammary cancer MCF-7, prostate cancer PC3M, and renal cancer RXF 631L. 
Trioxacarcin A was the most potent of all trioxacarcins, and gutingimycin was the less active with a 
mean IC70 value of 3.386 μg/mL. Trioxacarcin A also proved to be very toxic in preliminary in vivo 
experiments in tumor bearing nude mice, being the maximum tolerated dose between 0.1 and 0.3 
mg/kg. Trioxacarcins B to D showed selective antitumor activity against certain tumor cell lines [83]. 
Another compound from the same family, 1,8-dihydroxy-2-ethyl-3-methylanthraquinone, has been Mar. Drugs 2009, 7                                    
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identified from cultures of Streptomyces sp. FX-58, which was isolated from marine plant Salicornia 
herbacea collected in Qingdao, Shandong province, China. This compound showed inhibitory effect 
against human tumor cell lines of pro-myelocytic leukemia HL-60, gastric carcinoma BGC-823 and 
adenocarcinoma MDA-MB-435 with IC50 of 6.83, 82.2 and 56.59 µg/mL, respectively [86]. 
Tetracenomycin D and other quinone-related compounds with antitumor activity have been isolated 
from different marine acinomycetes (Figure 6). S. chinaensis AUBN1/7 isolated from marine sediment 
samples of Bay of Bengal, India, is the producer of 1-hydroxy-1-norresistomycin and resistoflavin 
[87]. These compounds together with resistomycin and tetracenomycin D are produced by 
Streptomyces sp. B8005 isolated from sediments of the Laguna de Términos at the Gulf of México 
[88]. Resistomycin was isolated, in addition, from Streptomyces sp. B4842 from mud sediment of a 
coastal site of Mauritius, Indian Ocean [88]. Tetracenomycin D was previously showed to possess 
cytotoxic activity [89] and it has been isolated from S. glauscescens as an intermediate in the 
biosynthesis of tetracenomycin D, whose biosynthesis gene cluster has been studied and used for the 
generation of several derived compounds [90]. Resistomycin, among other activities, has also been 
proposed to be a modulator of apoptosis [91]. The biosynthesis gene cluster of resistomycin has been 
isolated and characterized from S. resistomycificus, and, as expected, involves a type II PKS [92]. 1-
hydroxy-1-norresistomycin [87] and resistoflavin [93] showed cytotoxic activity against human gastric 
adenocarcinoma HMO2 and hepatic carcinoma HePG2 cell lines. 
 
Figure 6. Structures of anthraquinone and quinone-related compounds. 
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Two new cytotoxic quinones of the angucycline class, marmycins A and B (Figure 7) were isolated 
from the culture broth of Streptomyces strain CNH990 isolated from a sediment sample collected at a 
depth of 20 m at the entrance to the Sea of Cortez, 5 km east of Cabo San Lucas, México [94]. In 
cytotoxic assays using the human cell line of colon adenocarcinoma HCT-116, marmycin A showed an 
IC50 of 60.5 nM, almost 18 times more potent than marmycin B, which showed an IC50 of 1.09 μM. 
Marmycin A was further evaluated for its in vitro cytotoxicity showing a mean IC50 value of 0.022 μM 
against 12 human tumor cell lines (breast, prostate, colon, lung, leukemia). In the same assays 
marmycin B was significantly less potent with a mean IC50 value of 3.5 μM [94]. SS-228 Y (Figure 7) 
is an angucycline type compound [95] produced from a species of Chainia (now Streptomyces) 
isolated from shallow sea mud in Sagami Bay. During SS-228 Y structural characterization this 
compound was found to be very labile to light and heat, being converted into the anthracycline like 
compound SS-228 R [95,96]. SS-228 Y inhibits growth of Ehrlich breast adenocarcinoma in mice. A 
prolongation of the survival period was observed in mice inoculated with Ehrlich ascites tumor when 
SS-228 Y was administered for 10 days at doses of more than 1.56 µg per day. The acute toxicity of 
SS-228 Y, shown by LD50, in mice was between 1.56 and 6.25 mg/kg by intraperitoneal injection [97]. 
 
Figure 7. Structures of angucyclines and related compounds. 
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IB-00208 (Figure 7) is a polycyclic xanthone related to angucyclines and other aromatic 
polyketides [98]. It was isolated from Actinomadura sp BL-42-PO13-046 collected in the northern 
coast of Spain associated to a polychaete. IB-00208 showed a potent cytotoxic activity against mouse 
leukemia P-388 and human lung non-small cell A-549, colon adenocarcinoma HT-29 and melanoma 
SK-MEL-28 cell lines [99]. Griseorhodin A (Figure 7) [100], that belongs to the family of pentangular 
polyphenols related to angucyclines and other aromatic polyketides, is an inhibitor of human 
telomerase [101], a ribonucleoprotein complex involved in the stabilization of telomere length in stem 
cells and reproductive cells and found in almost all human tumors but not in adjacent normal cells 
[102]. The biosynthesis gene cluster for griseorhodin A has been isolated and characterized from Mar. Drugs 2009, 7                                    
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Streptomyces sp. JP95 associated with the marine ascidian Aplidium lenticulum collected at Heron 
Island, Queensland, Australia [103]. 
 
3. Non-Ribosomal Peptides  
 
This class of natural products comprises peptides synthesized by non-ribosomal peptide synthetases 
(NRPS). The amino acid monomers incorporated by NRPS assembly lines are aminoacyl-AMP mixed 
anhydrides that follow the same chemical logic as PKSs for chain elongation and are then modified 
based on the program encoded by different domains present in NRPS modules, which can include 
epimerization, methyltransferase, reductase or oxidase activities. Quite often non-ribosomal peptides 
also contain some unique structural features such as heterocyclic elements and deoxysugars [104-106].  
 
Figure 8. Structures of proximicins, lucentamycins and mechercharmycins. 
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Proximicins (Figure 8) are aminofuran antibiotics, probably synthesized by a NRPS system, 
produced by Verrucosispora strain MG-37 and V. maris AB-18-032, and isolated from sediments 
collected at a depth of 250 m in the Raune Fjord, Norway and the Sea of Japan at a depth of 289 m, 
respectively [107,108]. Proximicins A, B and C showed significant growth inhibitory activities 
towards human gastric adenocarcinoma AGS (GI50 of 0.6, 1.5 and 0.25 µM, respectively) and 
hepatocellular carcinoma Hep G2 (GI50 of 0.82, 9.5 and 0.78 µM, respectively) [107,109], and were 
found to induce arrest AGS cells in G0/G1 and to increase the levels of p53 and p21 [109]. 
Lucentamycins (Figure 8), 3-methyl-4-ethylideneproline-containing peptides, are produced by 
Nocardiopsis lucentensis strain CNR-712 isolated from sediment collected from a shallow saline pond 
on the island of Little San Salvador, in the Bahamas. Lucentamycins A and B showed significant in 
vitro cytotoxicity against human colon carcinoma HCT-116 cell line with IC50 values of 0.20 and 11 
µM, respectively. However, lucentamycins C and D were not cytotoxic in the same assay suggesting 
that the presence of an aromatic ring is essential for the biological activity of this class of compounds 
[110]. Mechercharmycins (Figure 8) are produced by Thermoactinomyces sp. YM3-251, isolated from 
sea mud collected at Mecherchar in the Republic of Palau (North Pacific Ocean). While 
mechercharmycin A showed cytotoxic activity against human lung adenocarcinoma A549 and Jurkat 
leukemia cells with IC50 values of 0.04 µM, mechercharmycin B did not show inhibitory activity in 
these assays even at 1 µM, which suggests the cyclic structure of mechercharmycin A must be 
essential for the antitumor activity [111]. 
Thiocoraline (Figure 9) is a 2-fold symmetric bicyclic non-ribosomally synthesized 
octathiodepsipeptide, characterized by the presence of peptide and ester bonds, produced by 
Micromonospora sp. L-13-ACM2-092 isolated from a soft coral collected at the Indian Ocean near the 
coast of Mozambique [112,113]. It shows potent antitumor activity against murine leukemia P388, 
human lung adenocarcinoma A549, and melanoma MEL288, being the activity against these cell lines 
5-fold more potent than for human colon adenocarcinoma HT-29 cell line (IC50 values of 0.002 vs. 
0.01 µM, respectively) [112]. In addition, on both LOVO and SW620 human colon cancer cell lines, 
thiocoraline caused an arrest in G1 phase of the cell cycle and a decrease in the rate of S phase 
progression towards G2/M phases, due to its DNA bisintercalative properties and its DNA polymerase 
α inhibition [114]. Thiocoraline is structuraly related to other bisintercalator compounds of the 
quinoxaline family with potential therapeutic applications like echinomycin, inhibitor of hypoxia-
inducible factor-1 that controls genes important for tumor progression and metastasis that are involved 
in glycolysis, angiogenesis, migration, and invasion [115]. The biosynthesis gene cluster of 
thiocoraline has been isolated, characterized and heterologously expressed in S. lividans and   
S. albus [116].  
Three new cyclohexadepsipeptides, arenamides (Figure 9), were isolated from the fermentation 
broth of a marine bacterial strain identified as S. arenicola CNT-088 which was obtained from a 
marine sediment sample collected at a depth of 20 m off the Great Astrolab Reef, in the Kandavu 
Island chain, Fiji. Arenamides A and B exhibited weak in vitro cytotoxicity against human colon 
carcinoma HCT-116 with IC50 values of 13.2 and 19.2 μg/mL, respectively [117].  
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Figure 9. Structures of depsipeptides thiocoraline, arenamides and piperazimycins. 
Thiocoraline
N
OH
H
N
O
O HN
S
O
SCH3
N
H3C
O
O
N
H3C
S
N
HO
N
H
O
O NH
S
O
H3CS
N
CH3
O
O
N
CH3 S
N
H
O O
H3C
CH3
H
N
O
O
H
N
O
CH3
CH3 H3C
HN
O
NH
O
CH3
CH3
Arenamide A
Arenamide B
Arenamide C
N
H
O O
H3C
CH3
H
N
O
O
H
N
O
CH3
CH3 H3C
HN
O
NH
O
CH3
CH3
N
H
O O
H3C
CH3
H
N
O
O
H
N
O
CH3
CH3 H3C
HN
O
NH
O
CH3
CH3
S
H3C
Piperazimycin A   R1= OH    R2= CH3
Piperazimycin B   R1= H       R2= CH3
Piperacimycin C  R1= OH    R2= CH2-CH3
N
NH
O
O
O
O
ON H
HN
O
N
O
N HN
HN
CH3
HO
CH3
OH
R2
Cl
R1
 
 
In addition, arenamides have been associated to chemoprevention of carcinogenesis by suppression 
of NFκB activation. NFκB regulates the expression of a number of genes, the products of which are 
involved in tumorigenesis [118,119]. The effect of arenamides on NFκB activity was studied with 
stably transfected 293/NFκB-Luc human embryonic kidney cells induced by treatment with tumor 
necrosis factor (TNF). Arenamides A and B blocked TNF-induced activation in a dose- and time-
dependent manner with IC50 values of 3.7 and 1.7 μM, respectively [117]. Piperazimycins (Figure 9) 
are cyclic hexadepsipeptides isolated from the fermentation broth of a Streptomyces sp. strain CNQ-
593, cultivated from marine sediments samples collected at a depth of approximately 20 m near the 
island of Guam. Antitumor activities for piperazimycins were initially evaluated in vitro against the 
human colon carcinoma HCT-116 cell line. All compounds exhibited significant cytotoxicity with an 
average GI50 of 76 ng/mL for each. Piperazimycin A also showed potent biological activity when 
evaluated against the NCI’s cancer cell line panel, with mean GI50, TGI and LC50 values for all cell 
lines of 100 nM, 300 nM and 2 µM, respectively. Overall, piperazimycin A exhibited a nearly 3-fold 
more potent activity against solid tumors (average LC50 of 13.9 µM) than against the leukemia cell 
lines tested (average LC50 of 31.4 µM), being most active against the melanoma (average LC50 of 0.3 
µM), central nervous system (average LC50 of 0.4 µM), and prostate cell lines (average LC50 of 0.6 
µM) cancers [120].  
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4. Mixed Polyketide-Nonribosomal Peptides 
 
As mentioned above, NRPSs and type I PKSs are multifunctional proteins that are organized into 
modules and use a similar strategy for the assembly of these two distinct classes of natural products. 
The combined use of NRPSs and type I PKSs allows assembling hybrid polyketide/non-ribosomal 
peptide compounds derived from amino acids and short-chain carboxylic acids.
  
The most known compound of this family is  salinosporamide A (Figure 10), a highly potent 
inhibitor of the 20S proteasome currently in phase I clinical trials for the treatment of cancer [76]. It is 
produced by S. tropica strain CNB-392 isolated from a sediment sample collected at a depth of about 1 
m from a mangrove environment in Chub Cay, Bahamas [121] and other S. tropica strains like CNB-
440 and CNB-476 isolated also from Bahamas [122,123]. Salinosporamide A displayed potent in vitro 
cytotoxicity against human colon carcinoma HCT-116 with an IC50 value of 11 ng/mL, and was shown 
potent and highly selective in the NCI’s 60 cell line panel. The greatest potency was observed against 
human cell lines of non-small cell lung cancer NCI-H226, central nervous system cancer SF-539, 
melanoma SK-MEL-28, and breast cancer MDA-MB-435 (all with LC50 values less than 10 nM). 
When salinosporamide A was tested against purified rabbit muscle 20S proteasome, a multicatalytic 
complex responsible for degrading most intracellular proteins in eukaryotes, it inhibited proteasomal 
chymotrypsin-like proteolytic activity with an IC50 value of 1.3 nM [121]. The 26S proteasome, 
composed of 19S and 20S components, is a multicatalytic complex responsible for degrading most 
intracellular proteins in eukaryotes. Three distinguishable proteolytic activities are localized in the 20S 
proteasome and are classified as chymotrypsin-, caspase-, and trypsin-like, all of them inhibited by 
salinosporamide A, in particular chymotrypsin and caspase-like [124].
 Compounds of the same family, 
salinosporamides B-J (Figure 10), have been isolated together with salinosporamide A from S. tropica 
[125-127]. In addition, new derivatives of salinosporamide A were produced by replacement of 
synthetic sea salt with sodium bromide in the fermentation media of S. tropica that led to the 
production of bromosalinosporamide [128], and by derivatization of salinosporamide A and B leading 
to the production of several thioester analogues (designed as T in Figure 10) [127]. Salinosporamide A 
thioester derivatives T1 and T2 were found potent 20S proteasome inhibitors with IC50 values of 3.6- 
and 1.5-fold higher than salinosporamide A [127]. The characterization of the salinosporamide A 
biosynthesis gene cluster during the sequencing of S. tropica CNB-440 circular genome [122] has 
allowed the generation of several derivatives such as fluorosalinosporamide produced by 
mutasynthesis using a chlorinase salL mutant [129], and antiprotealide (Figure 10) produced by a 
combination of genetic engineering and precursor-directed biosynthesis [130]. Antiprotealide has been 
recently found as a natural product produced by different strains of S. tropica [131].  
Lajollamycin (Figure 10) is another mixed polyketide/non-ribosomal peptide produced by S. 
nodosus strain NPS007994 isolated from marine sediments collected in Scripps Canyon, La Jolla, 
California. Lajollamycin was found to inhibit the growth of murine melanoma cell line B16-F10, with 
an EC50 of 9.6 µM [132]. The biosynthesis gene cluster of oxazolomycin, a structural close relative of 
lajollamyin, has been isolated and characterized from S. albus JA3453 confirming the hybrid peptide-
polyketide origin of these compounds [133].  
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Figure 10. Structures of mixed polyketide/non-ribosomal peptide compounds. 
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5. Isoprenoids  
 
Isoprenoids, similar to terpenes, are one of the largest families of natural compounds. Isoprenoids 
are derived from five-carbon isoprene units assembled and modified in different ways. They are 
classified into several groups based on the number of C5 units that form part of their structure: 
monoterpenes (C10), sesquiterpenes (C15) and diterpenes (C20) [134]. Mar. Drugs 2009, 7                                    
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Altemicidin (Figure 11) with a monoterpene-alkaloid skeleton is produced by S. sioyaensis SA-
1758 isolated from sea mud collected at Gamo, Miyagi Prefecture, Japan [135]. This compound was 
found to inhibit the growth of murine lymphoid leukemia L1210 and carcinoma IMC cell lines with 
IC50 values of 0.84 and 0.82 µg/mL, respectively, although it showed high acute toxicity in mice [136]. 
 
Figure 11. Structures of monoterpenes and sesquiterpenes isolated from marine 
actinomycetes. 
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Marinones (Figure 11) are sesquiterpenoid naphthoquinones with a mixed polyketide-terpenoid 
origin [137]. Neomarinone, isomarinone, hydroxydebromomarinone and methoxydebromomarinone 
were produced by actinomycete isolate CNH-099 obtained from a sediment sample taken at 1 m depth 
in Batiquitos Lagoon, North of San Diego, California. These compounds showed moderate in vitro 
cytotoxicity, IC50 of 8 µg/mL, against human colon carcinoma HCT-116 cells. In addition, 
neomarinone generated a mean IC50 value of 10 µM in the NCI’s 60 cancer cell line panel [138,139]. 
T-muurolol sesquiterpernes (Figure 11) were isolated from Streptomyces strain M491 derived from 
sediment obtained from Jiaozhou Bay, Qingdao coast, China [49,140]. Seven out of eight 
sesquiterpenes of the T-muurolol family were tested for their cytotoxycity against 37 human tumor cell 
lines but, except for 15-hydroxy-T-muurolol which was moderately cytotoxic with an IC50 of 6.7 
μg/mL, the other compounds including 3-oxo-T-muurolol, 11,15-dihydroxy-T-muurolol, T-muurolol 
and 3α-hydroxy-T-muurolol showed no activity [140]. 
Several chlorinated dihydroquinones (1-5, Figure 12), with a mixed terpenoid/polyketide origin, are 
produced in saline culture of the actinomycete strain CNQ-525, isolated from ocean sediments 
collected at a depth of 152 m near La Jolla, California [141]. Dihydroquinones 4 and 5 were identical 
to the previously reported antibiotics A80915A and A80915C produced by soil actinomycete S. Mar. Drugs 2009, 7                                    
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aculeolatus [142]. Dihydroquinones 1,  2 and 4 were found to be cytotoxic toward human colon 
carcinoma HCT-116 cells with IC50 of 2.4, 0.97 and 1.84 µg/mL, respectively [141].  
Actinobacterium sp. MS1/7 isolated form sediments taken at the Bay of Bengal is the producer of 
compound 4a,8a-dimethyl-6-(2-methyl-propenyloxy)-3,4,4a,4b,5,6,8a,9-octahydro-1H-phenanthren-2-
one (Figure 12), with putative isoprenoid origin. This compound was found to inhibit the growth by 
54% of human leukemia HL-60 cell line at 0.05 µg/mL and to possess a reduced toxicity against non-
tumor cells since only 2.3% of murine erythrocytes and 1.6% of human erythrocytes were lysed at 
concentrations of 35-40 µg/mL [143]. 
 
Figure 12. Structures of chlorinated dihydroquinones and active compound from strain 
MS1/7. 
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6. Indolocarbazoles  
 
Most of the compounds of this family contain a characteristic indolo[2,3-a]pyrrolo[3,4-c]carbazole 
core derived from two units of tryptophan, with sugars attached derived from glucose and methionine. 
These compounds constitute a separate type of antitumor drugs with several mechanisms of action 
including DNA-damage targeting on topoisomerases I and II, and inhibition of protein kinases, 
including serine/threonine and tyrosine kinases [144]. One of the better known indolocarbazole, 
staurosporine (Figure 13) has been isolated from several marine actinomycetes including 
komodoquinones-producer  Streptomyces sp. KS3 [74] after its discovery from cultures of S. 
staurosporeus AM-2282 [145]. The staurosporine biosynthesis gene cluster was identified and 
characterized from Streptomyces sp. TP-A0274 and S. longisporoflavus [146,147], which has led to the 
generation of several derivatives of indolocarbazoles staurosporine and rebeccamycin with antitumor Mar. Drugs 2009, 7                                    
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activity [147-150]. Staurosporine has been isolated, in addition, together with two natural analogues, 
4’-N-methyl-5’-hydroxystaurosporine and 5’-hydroxystaurosporine (Figure 13) from Micromonospora 
sp. L-31-CLCO-002 obtained from a homogenate of the sponge Clathrina coriacea collected on the 
Coast of Fuerteventura Island in the Canary Islands archipelago [151].  
 
Figure 13. Structures of indocarbazoles and bisindole pyrroles produced by marine 
actinomycetes. 
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The cytotoxic activities of these indolocarbazoles were determined in vitro in cell cultures of 
murine macrophague P388D1 (IC50 of 0.01, 0.02 and 0.04 µg/mL), human lung adenocarcinoma A549 
(IC50 of 0.0005, 0.002 and 0.004 µg/mL), colon adenocarcinoma HT-29 (IC50 of 0.02, 0.004 and 0.004 
µg/mL) and melanoma SK-MEL-28 cell lines (IC50 of 0.001, 0.002 and 0.004 µg/mL). Staurosporine 
showed the strongest activity against P388D1, A549 and SK-MEL-28 cell lines, while 4’-N-methyl-5’-
hydroxystaurosporine and 5’-hydroxystaurosporine were more active against HT-29 cell line [151]. N-
formyl- and N-carboxamido-staurosporines have been isolated from cultures of Streptomyces sp. 
QD518 isolated from the Jiaozhou Bay of Quindao, China [75]. N-formyl- and N-carboxamido-
staurosporines were tested in vitro for antitumoral activity in a panel of 37 human tumor cell lines 
derived from solid human tumors. N-carboxamido-staurosporine was found to be the most potent 
compound with a mean IC50 and IC70 values of 0.016 and 0.17 µg/mL, respectively, while N-formyl-
staurosporine showed also high activity with mean IC50 and IC70 values of 0.063 and 0.37 µg/mL, 
respectively [75]. ZHD-0501 (Figure 13) is a novel naturally occurring staurosporine analog carrying a Mar. Drugs 2009, 7                                    
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heterocycle fused to the pyran ring produced by Actinomadura sp. 007, strain isolated from a sea 
sediment sample collected in Jiaozhou Bay, China [152]. ZHD-0501 was shown to inhibit the 
proliferation of human lung adenocarcinoma A549, hepatocarcinoma BEL-7402, and pro-myelocytic 
leukemia HL60 cancer cell lines and mouse leukemia P388 cells with the inhibition rates of 82.6%, 
57.3%, 76.1%, and 62.2% at 1 µM, respectively. It also inhibited the proliferation of mouse mammary 
cancer tsFT210 cells, by inhibiting the cell cycle at the G2/M phase, with the inhibition rates of 28.3% 
at 21 µM and 20.5% at 2.1 µM [152]. 
Two known indolocarbazole alkaloids with anticancer properties, K252c (staurosporine aglycon) 
and arcyriaflavin A (Figure 13), are produced by marine actinomycete strain Z2039-2, isolated from 
the sea sediment collected on the coast of Qingdao, China. K252c was found to induce 57.3% 
apoptosis on culture of human chronic myelogenous leukemia K562 cell line at 10 µM and nearly 
100% at 100 µM. In the same assay arcyriaflavin A induced 25.9% apoptosis at 10 µM and up to 
68.93%, at 100 µM [153]. K252c and arcyriaflavin A have been found, in addition, to reduced the 
relative resistance of cells transfected with ABCG2, a transporter with potential importance in cancer 
drug resistance, to SN-38 (7-ethyl-10-hydroxycamptothecin) in cytotoxicity assays [154]. Several 
analogues of K252c and arcyriaflavin A have been generated using genes involved in rebeccamycin 
biosynthesis [149].  
Lynamicins (Figure 13) bisindole pyrroles are related to bisindolylmaleimides and indolocarbazoles 
due to their close structural and biosynthetic relationships [144], are produced by Marinispora sp. 
NPS12745 isolated from a marine sediment collected off the coast of San Diego, California. These 
compounds have been only tested for antimicrobial activity showing good potency against 
staphylococci and enterococci [155]. However, there are reports of bisindolylmaleimide derivatives 
with potent antitumor and antiangiogenic properties [144] and with potential to reduce resistance 
mediated by transporter ABCG2 [154]. 
 
7. Others  
 
Marineosins (Figure 14), related to the prodigiosin class of polypyrrole bacterial pigments, are 
spiroaminal compounds containing two pyrrole functionalities produced by Streptomyces strain CNQ-
617 isolated from a marine sediment sample collected off shore of La Jolla, California. Marineosins 
showed significant inhibition of human colon carcinoma HCT-116 cell line with IC50 values of 0.5 μM 
for marineosin A and 46 μM for marineosin B. These differences might be due to the configuration at 
the spiroaminal center. In addition, marineosin A showed selectivity against melanoma and leukemia 
cell lines in the NCI’s 60 cell line panel [156]. Additionally, two known compounds of the prodigiosin 
family have been isolated from cultures of Saccharopolyspora sp. nov. actinomycete isolated from 
sponge Mycale plumose collected along the coast of Qingdao, China [157]. The compounds identified 
as metacycloprodigiosin and undecylprodigiosin [158,159] exhibited significant cytotoxic activities in 
vitro, as it has been recently described for prodigiosin family of compounds [160], against five cancer 
cell lines: mouse lymphoma P388, human peripheral blood promyeloblast HL60, lung carcinoma A-
549 and SPCA4, and hepatic carcinoma BEL-7402 with IC50 values between 0.007 and 7.52 µM for 
metacycloprodigiosin and 0.013 to 0.11 µM for undecylprodigiosin [157].  Mar. Drugs 2009, 7                                    
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Streptopyrrolidine (Figure 14) is a benzyl tetrahydropyrrole derivative produced by Streptomyces 
sp. KORDI-3973 isolated from a deep-sea sediment sample collected at Ayu Trough, in the southern 
Philippine Sea. Streptopyrrolididine showed anti-angiogenesis activity on human umbilical vein 
endothelial cells (HUVECs) based capillary tube formation assay. The inhibition of tube formation 
was exerted without showing cytotoxicity against HUVECs at the concentration of 100 µg/mL [161]. 
 
Figure 14. Structures of polypyrrole, tetrahydropyrrole, pyrroloiminoquinone and 
pyrrolizidine compounds. 
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Ammosamides (Figure 14) are pyrroloiminoquinone compounds produced by Streptomyces strain 
CNR-698 isolated from bottom sediments collected at a depth of 1,618 m in the Bahamas Islands. 
Ammosamide A and B exhibited significant in vitro cytotoxicity against human colon adenocarcinoma 
HCT-116 cells with an IC50 of 320 nM each. These compounds were shown highly selective against a 
diversity of cancer cell lines with values ranging from 20 nM to 1 µM, indicating a specific target 
mechanism of action that was identified as a member of the myosin family, important cellular proteins 
that are involved in numerous cell processes, including cell cycle regulation, cytokinesis, and cell 
migration [162]. 
Bohemamines (Figure 14) are pyrrolizidine alkaloids produced by Streptomyces strain CNQ-583 
cultured from a marine sediment sample collected at a depth of 82 m off the island of Guam. 
Bohemamine, bohemamine B, bohemamine C and 5-chlorobohemamine C were tested for inhibition of 
the human colon adenocarcinoma HCT-116 cell line but were found to be inactive [163]. However, 
bohemamine and deoxybohemamine were shown to be inhibitors of cell adhesion based on LFA-
1/ICAM-1 capable of inhibiting adhesion of human pro-myelocytic leukemia HL-60 cells to Chinese 
hamster ovary cells transfected with human ICAM-1, at IC50 values of 24.3 and 27.2 µg/mL, 
respectively [164]. The interaction between LFA-1, also frequently expressed on hematopoietic and Mar. Drugs 2009, 7                                    
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solid cancer cell types, and ICAM-1, that in its circulating form promotes angiogenesis and alters 
cancer cell behavior, is implicated in inflammatory pathologies, autoimmune diseases and in many 
cancer processes such as cancer metastasis from gastrointestinal carcinoma, melanoma and lymphoma. 
This interaction is a promising target for the development of new therapeutic agents [165, 166]. 
Three new cytotoxic 3,6-disubstituted indoles (Figure 15), with an isoprene unit at carbon 6, were 
isolated from Streptomyces strain BL-49-58-005 isolated from an unidentified marine invertebrate 
collected in México. These compounds are probably the products of different steps along the same 
biosynthetic pathway starting from tryptophan or tryptamine as presumed precursors. These indole 
compounds were assayed against a panel of 14 different tumor cell lines. Indole 1 (6-prenyltryptophol) 
showed the best activity against human leukemia K-562 cell line with a GI50 value of 8.46 µM. The 
aldoxime indole 2 showed activity with GI50 values within µM range against human prostate cancer 
LN-caP, endothelial cancer HMEC1, leukemia K-562, pancreatic carcinoma PANC1, and colon 
adenocarcinoma LOVO and LOVO-DOX cell lines. Nitrile indole 3 showed no activity [167]. 
Streptochlorin (Figure 15) is a 3-substituted indole compound with antiangiogenic and anticancer 
activities produced by Streptomyces strain 04DH110 isolated from shallow water sediment taken at 1 
m depth of Ayajin Bay, on the East Sea of Korea. Streptochlorin exhibited significant in vitro growth 
inhibitory activity against human leukemia K-562 cells with an IC50 of 1.05 μg/mL [168]. The 
apoptosis effect induced by streptochlorin was investigated in human leukemic U937 and 
hepatocarcinoma Hep3B cells showing it was correlated with a decrease in the mitochondrial 
membrane potential, activation of caspase-3, and down-regulation of antiapoptotic Bcl-2 protein. 
Those effects were exerted through production of reactive oxygen species in Hep3B cells. In U937 
cells up-regulation of pro-apoptotic Bax and FasL, and degradation of poly-(ADP-ribose)polymerase 
and phospholipase C-γ1 protein was also observed [169,170]. Streptochlorin was found to have, in 
addition, a potent antiangiogenic activity by inhibition of endothelial cell invasion and tube formation 
stimulated with vascular endothelial cell growth factor, probably by inhibition of TNF-α-induced NF-
κB activation [171]. 
Caboxamycin (Figure 15) is a benzoxazole compound produced by Streptomyces sp. NTK 937 
isolated from an Atlantic Ocean deep-sea sediment collected in the Canary Basin. It was tested against 
different tumor cell lines and showed moderate growth inhibitory activity towards human gastric 
adenocarcimona AGS, hepatocellular carcinoma Hep G2 and breast carcinoma MCF7 cell lines with 
GI50 of 7.5, 7.4 and 7.3 µg/mL, respectively [172]. 
Streptokordin (Figure 15) is a methylpyridine compound produced by Streptomyces Sp. KORDI-
3238 isolated from deep-sea sediments at Ayu Trough. It exhibited significant in vitro antitumor 
activity against human breast cancer MDA-MB-231, colon cancer HCT 15, prostate cancer PC-3, lung 
cancer NCI-H23, renal cancer ACHN, skin cancer LOX-IMVI and leukemia K-562 cell lines with IC50 
values raging from 3.2 to 8.6 µg/mL. Streptokordin did not show inhibitory effect at the concentration 
of 1 mg/mL on the growth of any Gram-positive or -negative bacteria or fungus tested [70]. 
S. luteoverticillatum 11014 [173] isolated from underwater sediment at 20 m depth collected off the 
coast of Taipingjiao, Qingdao, China, is the producer of four known butenolides: (4S)-4,10-dihydroxy-
10-methyl-undec-2-en-1,4-olide [174], (4S)-4,10-dihydroxy-10-methyl-dodec-2-en-1,4-olide 
[174,175], and two diastereomeric (4S)-4,11-dihydroxy-10-methyl-dodec-2-en-1,4-olides (Figure 15) 
[175]. The four butenolides showed cytotoxic activity against human leukemia K562 with IC50 values Mar. Drugs 2009, 7                                    
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of 8.73, 6.29, and 1.05 µmol/mL and murine lymphoma P388 cell lines with IC50 values of 0.34, 0.19, 
and 0.18 µmol/mL, respectively. The mixture of butenolides 3 and 4, (4S)-4,11-dihydroxy-10-methyl-
dodec-2-en-1,4-olides, was the most active, but it was unknown if both of the diastereomers were 
active [173].  
 
Figure 15. Structure of indole, benzoxazole, methylpiridine and butenolide compounds. 
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Actinomadura sp. M048 derived from sediments of Jiaozhou Bay in China is the producer of known 
phenazine compounds iodinin [176] and 1,6-phenazinediol [177], the phenoxazin-3-one compounds 
questiomycin A and N-acetylquestiomycin A [178], and three new phenoxazin-3-one antibiotics 
chandrananimycins A, B and C (Figure 16) [179]. Questiomycins and chandrananimycins were found 
to be active against human colon carcinoma CCL HT29, melanoma MEXF 514L, lung carcinoma 
LXFA 526L and LXFL 529L, breast carcinoma CNCL SF268, LCL H460 and MACL MCF-7, 
prostate cancer PRCL PC3M and renal cancer RXF 631L cell lines with IC70 values down to 1.4 
µg/mL. Iodinin and 1,6-phenazinediol exhibited antitumor activity against the human lung carcinoma 
LXFA 629L and LXFL 529L, breast cancer MAXF 401NL, melanoma MEXF 462NL, renal cancer 
RXF 944L and uterus cancer UXF 1138L cell lines with IC50 values of 3.6 and 3.2 μg/mL,  
respectively [179]. 
Echinosporin and 7-deoxyechinosporin (Figure 16), tricyclic acetal-lactones, are produced by S. 
albogriseolus A2002 isolated from a sea sediment sample collected in Jiaozhou Bay, China [180] and 
have been previously described as produced by S. echinosporus MK-213 [181] and by Sac. erythraea 
Tü 4015 (formerly S. erythraeus) where it was shown by feeding experiments that echinosporin is 
synthesized by the shikimate pathway with chorismate as a biosynthetic intermediate [182]. 
Echinosporin was shown to inhibit the proliferation of human myelogenous leukemia K562, colon 
carcinoma HCT-15 and mouse mammary carcinoma tsFT210 cell lines in vitro [180], human breast 
adenocarcinoma MCF7, hepatocellular carcinoma Huh7 and HepG2 cell lines in vitro [182] and on 
rodent tumor models such as leukemia P388, P388/VCR, and fibrosarcoma Meth 1 in vivo [183]. 7-Mar. Drugs 2009, 7                                    
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deoxyechinosporin showed a weaker effect than echinosporin on K562, HCT-15 and tsFT210 cell lines 
[180]. Both compounds were shown to arrest the cell cycle of K562, HCT-15 and tsFT210 cells mainly 
at the G2/M phase and to induce apoptosis in these cells [180]. 
 
Figure 16. Structures of phenazine, phenoxazin-3-one and tricyclic acetal-lactone 
compounds. 
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Apart of the antitumor compounds produced by marine actinomycetes depicted above, there are 
several additional compounds with antitumor activity like the topoisomerase I inhibitors cyclopropane 
and 14-methylhexadecanoic fatty acids produced by Streptomyces sp. strain KM86-913, isolated from 
a marine sponge collected under the seashore of Keomun Island, Korea [184]. In other cases the 
compounds identified are yet uncharacterized as is the case of light-activated cytotoxic compounds 
produced by different microorganisms, including actinomycetes isolated from marine sponges 
collected from various places in the coast of Peninsular Malaysia [185].  
 
8. Conclusions  
 
Actinomycetes and, in particular the genus Streptomyces, have been well known during the last 
seventy years as prolific producers of new bioactive compounds, antitumor drugs included. With the 
increasing development of oceanographic studies leading to the isolation of new actinomycetes from 
marine sources, new prolific genera in the production of useful compounds have been found, such as 
Salinispora. However, the Ocean, without any doubt, is keeping a myriad of new actinomycetes 
providing novel structural diversity to be discovered and used. In addition, the continuous effort for 
unravel the biosynthesis of the already known compounds and the isolation and characterization of 
their biosynthesis gene clusters will lead to the development of new antitumor compounds, hopefully 
with improved therapeutic properties, by using combinatorial biosynthesis approaches.  
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